

RESEARCH

Open Access



# Modified regimen intrapleural alteplase with pulmozyme in pleural infection management: a tertiary teaching hospital experience

Xiong Khee Cheong<sup>1</sup>, Andrea Yu-Lin Ban<sup>1</sup>, Boon Hau Ng<sup>1</sup>, Nik Nuratiqah Nik Abeer<sup>1</sup>, Nik Azuan Nik Ismail<sup>2</sup>, Nik Farhan Nik Fuad<sup>2</sup>, Syed Zulkifli Syed Zakaria<sup>3</sup>, Sheah Lin Ghan<sup>4</sup> and Mohamed Faisal Abdul Hamid<sup>1\*</sup>

## Abstract

**Background:** Current management of poorly draining complex effusions favours less invasive image-guided placement of smaller tubes and adjunctive intrapleural fibrinolysis therapy (IPFT). In MIST-2 trial, intrapleural 10 mg alteplase (t-PA) with 5 mg of pulmozyme (DNase) twice daily for 72 h were used. We aimed to assess the effectiveness and safety of a modified regimen 16 mg t-PA with 5 mg of DNase administered over 24 h in the management of complex pleural infection.

**Methods:** This was a single centre, prospective study involving patients with poorly drained pleural infection. Primary outcome was the change of pleural opacity on chest radiograph at day 7 compared to baseline. Secondary outcomes include volume of fluid drained, inflammatory markers improvement, surgical referral, length of hospitalisation, and adverse events.

**Results:** Thirty patients were recruited. Majority, 27 (90%) patients were successfully treated. Improvement of pleural opacity on chest radiograph was observed from 36.9% [Interquartile range (IQR 21.8–54.9%)] to 18.1% (IQR 8.8–32.7%) of hemithorax ( $P < 0.05$ ). T-PA/DNase increased fluid drainage from median of 45 mls (IQR 0–100) 24 h prior to intrapleural treatment to 1442 mls (IQR 905–2360) after 72 h; ( $P < 0.05$ ) and reduction of C-reactive protein ( $P < 0.05$ ). Pain requiring escalation of analgesia affected 20% patients and 9.9% experienced major adverse events. None required surgical intervention.

**Conclusion:** This study suggests that a modified regimen 16 mg t-PA with 5 mg DNase can be safe and effective for patients with poorly drained complex pleural infection.

*Trial registration* The study was registered retrospectively on 07/06/2021 with ClinicalTrials number NCT04915586 (<https://clinicaltrials.gov/ct2/show/NCT04915586>).

**Keywords:** Intrapleural fibrinolysis, Pleural infection, Empyema, Alteplase, DNase

## Background

Pleural infection causes significant morbidity and mortality. Treatment goals involve antibiotic therapy and drainage of infected pleural fluid. However, unsatisfactory drainage can occur due to septations or loculated effusion. Surgery is indicated when medical therapy fails.

\*Correspondence: [faisal.hamid@ppukm.ukm.edu.my](mailto:faisal.hamid@ppukm.ukm.edu.my)

<sup>1</sup> Respiratory Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Kuala Lumpur, Malaysia

Full list of author information is available at the end of the article



Recently, there is a paradigm shift to less invasive approach using intrapleural fibrinolytic therapy (IPFT) in complex effusion for patients who fail standard care and unfit for surgical intervention [1–3]. Intrapleural streptokinase and urokinase had been studied with conflicting results [4, 5]. Currently, tissue plasminogen activator (t-PA) e.g. alteplase is the most commonly used agent [6].

Pulmozyme (DNase) has a synergistic effect with alteplase on the breakdown of fibrin in empyema and reduces viscosity thus promoting pleural fluid drainage. Intrapleural combination t-PA and DNase success has been shown in numerous trials [7–12]. In the Multi-Centre Intrapleural Sepsis-2 (MIST-2) trial, the use of t-PA with DNase improved the drainage in patients with complex effusion and reduced the frequency of surgical referrals [7].

As far as our knowledge, there is no optimal regimen of intrapleural fibrinolysis therapy [13, 14]. The dosage that utilised in MIST-2 trial which 10 mg t-PA (with supplementary 5 mg DNase) twice daily is still an empiric choice [7]. Abu-Daff et al. shown the effectiveness of intrapleural 16 mg t-PA alone in complex effusion with 6.6% bleeding events reported [15]. The rationale of using 16 mg t-PA in this study to simplify the pharmacy dispensary as in our formulary, one ampoule of alteplase contains 50 mg; t-PA biochemical stability up to 24 h following reconstitution as assessed by in vitro clot lysis assays [16]. We hypothesize that this modified regimen of t-PA 16 mg (with DNase 5 mg) is safe and effective for patients with poorly drained complicated pleural infection.

## Methods

We conducted a prospective open-label study on patients who were given intrapleural t-PA and DNase for pleural infection from December 2019 to October 2020 in Universiti Kebangsaan Malaysia (UKM) Medical Centre. Written informed consents were obtained from all patients prior to participation in this study according to institutional guidelines.

### Patient involvement

We included patients with pleural infection (complex parapneumonic effusion or empyema) with poor pleural fluid drainage of  $\leq 150$  mL after 24 h of insertion of chest drain. Pleural infection was defined as fulfilled  $\geq 2$  of the following characteristics: 1) clinical evidence of infection such as fever and or elevated C-reactive protein (CRP) or white-cell count (WCC). 2) complex pleural effusion proven by thoracic ultrasound is defined as presence of fibrin strands or septations within pleural cavity, proven by thoracic ultrasound. 3) pleural fluid that fulfilled at least one of the characteristics: frank pus, exudative nature (according to light's criteria), gram stain

or culture positive, lactate dehydrogenase (LDH)  $> 1000$  U/L, pH  $< 7.2$  and/or glucose level  $< 3.3$  mmol/L [7, 8]. The exclusion criteria were if candidates refused the trial, known allergy to t-PA or DNase, acute stroke, active bleeding diathesis, major surgery in past 5 days, previous pneumonectomy on the infected side, bronchopleural fistula, pregnancy or coagulopathy (INR  $> 2$ , APTT  $> 100$ , platelet count  $< 50,000$  cells).

All patients underwent ultrasound guided intercostal chest catheter (ICC) placement. Baseline chest radiograph was performed within 24 h prior to IPFT to ensure the ICC position. The standard regime in our study was t-PA 16 mg with DNase 5 mg. Both medications were diluted in 50 mL of 0.9% sodium chloride solution respectively. T-PA 16 mg was instilled first intrapleurally via ICC, which was then allowed to dwell for 45 min and then unclamped to allow free drainage for 45 min. The same procedure was then repeated for DNase 5 mg. Therapy was given 12 h apart for a maximum of 3 doses, depending on physician's judgement and clinical improvement. Intravenous tramadol 50 mg was administered prior to intrapleural alteplase as pre medication analgesia.

### Outcome measures

The primary outcome was the change in pleural opacity on hemithorax (measured in percentage), on chest radiograph at day 7 as compared to baseline. The pleural effusion volume was measured digitally (see Additional file 1) by two radiologists independently using Horos Project Software v3.3.5. [7, 17]. The radiologists were blinded to patient identity and intervention timing.

Secondary outcomes were the pleural fluid volume drained; the changes in inflammatory markers (CRP and WCC), length of hospitalisation, surgical intervention within 30 days and adverse events post therapy.

Treatment success defined as survival to hospital discharge without requiring surgical intervention within 30 days post first dose of intrapleural t-PA/DNase. Radiological improvement defined as reduction of pleural opacity  $\geq 15\%$  on day 7 chest radiograph compared to baseline. Treatment failure defined as failure of radiological resolution on chest radiograph, requirement of surgical intervention or mortality within 30 days post first dose of t-PA/DNase.

### Statistical analysis

The sample size was calculated on the basis of the estimated 95% confidence interval (95% CI) with population size taken from the previous study [18]. By using the formula with finite population correction (Daniel, 1999) with prevalence of 0.5 and precision of 5%, the sample size was 24.

Statistical analysis performed using SPSS software version 25 (IBM, Armonk, NY). All numerical data were subjected to normality testing using Kolmogorov–Smirnov test. Results presented as mean  $\pm$  standard deviation (SD) or median (IQR) based on the normality of data. The Wilcoxon signed rank test were used to analyse the changes of pleural opacity on chest x-ray and inflammatory markers following intrapleural therapy. For multiple group comparisons analysis, we used Friedman's analysis of variance on ranks (ANOVA), followed by post hoc test for pleural fluid drainage following intrapleural therapy. Significant was defined as  $P < 0.05$ .

### Ethical approval

The study was approved by the Research Ethics Committee board of UKM (FF-2020–008) and registered with Medical Research and Ethic Committee of the Ministry of Health Malaysia (NMRR-19–2940-51,404). The trial was registered retrospectively on 07/06/2021 with ClinicalTrials number NCT04915586. This was inadvertent and due to unawareness requirement on international registry. However, there were no protocol violation from when recruitment began to the registration of the trial. The authors confirm that all ongoing and related trials for this intervention are registered.

### Results

Total 40 patients with pleural infection were enrolled during the study period, 9 patients were excluded due to the following reasons: 2–recent abdominal operations, 1–bronchopleural fistula and 6–different regimen of t-PA/DNase (Fig. 1). There was 1 drop out as patient passed away for myocardial infarction before completion of study. Demographic characteristics are detailed in Table 1. Total of 30 patients [23 males] with a mean age of 55.7 years ( $\pm$  SD 19) received intrapleural t-PA/DNase. Four patients (13.3%) had carcinoma as major life limiting illness. All 30 patients (100%) had septations on thoracic sonography. The median pleural fluid LDH was 1034 U/L (IQR 550–4395) (Table 1). Positive microbial pleural fluid cultures were reported in 8 (26.7%) patients; 4 patients (16.7%) grew *Klebsiella pneumoniae sp* (Table 2).

The median pleural fluid volume drained 24 h prior to intrapleural therapy was 45 ml (IQR, 0–100). Majority (86.7%) were treated with small bore ( $\leq 15$  French) ICC. Eleven patients (36.7%) had more than 1 ICC inserted due to non–communicating locules of the effusion or chest drain dysfunction. Only 26.7% [8 patients] received  $\leq 2$  doses t-PA/DNase as effusion was completely drained before 3rd dose.

All 30 patients (100%) survived upon hospital discharge without requiring surgery (Table 3). No mortality due to pleural infection or directly related to t-PA/DNase

therapy during 30 days after hospital discharge. Three patients died after hospital discharge within 30 days following intrapleural therapy due to unrelated causes as their pleural infection had been controlled. One patient died 20 days after discharge due to progression of lung carcinoma and poor comorbidities; while another patient with advanced peritoneal liposarcoma with colon metastasis had recurrent gastrointestinal bleed 7 days following intrapleural t-PA/DNase. One patient was on dabigatran for atrial fibrillation; died 15 days after discharge due to traumatic brain injury following fall at home. Therefore, 90% (27 patients) were successfully treated and alive at 30 days without requiring surgical intervention.

The median length of hospital stay were 17 days (IQR, 11.7–24.2) (Table 3). The median duration of hospitalisation from first dose post intrapleural therapy were 8 days (IQR, 4.8–12).


Significant radiological improvement was observed with intrapleural t-PA/DNase (Fig. 2). Pleural opacity on chest x-ray (CXR) was reduced from a median of 36.9% (IQR, 21.8–54.9) on baseline chest x-ray to median of 18.1% (IQR, 8.8–32.7) after 7 days post intrapleural therapy ( $P < 0.001$ ).

The median (IQR) pleural fluid drainage 24 h before t-PA/DNase therapy was 45 ml (0–100), which increased to 710 ml (350–1225) at 24 h following the first dose t-PA/DNase and 1442 ml (905–2360 at 72 h of therapy ( $P < 0.001$ ) (Fig. 3).

There was significant reduction on CRP (normal range  $< 0.5$  mg/dL) with median (IQR) at baseline pretreatment of 11.4 mg/dL (4.5–19.4) to 5 mg/dL (1.8–10.4 mg/dL) by day 7 post intrapleural t-PA/DNase ( $P < 0.001$ ). However, there was no significant change in the median (IQR) on day 7 post therapy WCC of  $7.9 \times 10^9$  (6.1–11.0) from baseline  $8.2 \times 10^9$  (7.1–13.1) ( $P = 0.215$ ).

Three major adverse events (9.9%) were reported (Table 3); 2 events seen in one patient which include gastrointestinal (GI) bleed (3.3%) and hypotension (3.3%) while another patient had mild hemoptysis (3.3%). First patient had bleeding risk and advanced peritoneal liposarcoma with colon metastasis; not suitable for surgery. He developed GI bleed following first dose intrapleural t-PA/DNase which the treatment was ceased. His condition improved with blood transfusion and bleeder secured; sepsis was controlled with radiological improvement. However, GI bleed recurred 7 days after intrapleural t-PA/DNase was given and he passed away subsequently.

Second patient had one episode of hemoptysis (3.3%) after second dose t-PA/DNase. He was on dialysis for end stage renal disease. However, no evidence of pleural bleeding and patient remained hemodynamic stable throughout therapy.



Another patient had recent chemotherapy for diffuse B cell lymphoma. Total 2810 ml blood-stained pleural fluid was drained after three doses of t-PA/DNase. Her haemoglobin level gradually decreased (8.6 g/L to 7.8 g/L) without hemodynamic compromise. She was transfused one unit packed cell and was discharged well.

Six (20%) cases had chest pain within first 12 h following intrapleural therapy. All patients responded well to escalation of opioid analgesia without cessation of treatment.

**Table 1** Demographics and clinical characteristics

Demographic and characteristics	Values
Age (years), mean	55.7
Male sex, n (%)	23 (76.7)
Race, n (%)	
Malay	15 (50)
Chinese	13 (43.3)
Indian	2 (6.7)
Smoking History, n (%)	
Active smoker	9 (30)
Ex- smoker	9 (30)
Non smoker	12 (40)
Comorbidities, n (%)	30 (100)
Cardiovascular disease	
Hypertension	17 (56.7)
Ischemic heart disease	5 (16.7)
Atrial fibrillation	1 (3.6)
Congestive cardiac failure	2 (7.1)
Endocrine disease	
Diabetes mellitus	14 (46.7)
Respiratory disease	
Pulmonary tuberculosis (in the past)	2 (6.7)
Neurological disease	
Stroke	3 (10)
Renal disease	
Chronic kidney disease	3 (2 on dialysis) (10)
Malignancy	
Lung malignancy	2 (6.7)
Haematological malignancy	1 (3.3)
Retroperitoneal liposarcoma	1 (3.3)
Other	
HIV	2 (6.7)
Thalassemia major	1 (3.3)
Pleural infection characteristics	
Ultrasonographic evidence of septations, n (%)	30 (100)
Pleural fluid analysis	
Bacteria identified in pleural fluid culture, n (%)	8 (26.7)
Median LDH, U/L (IQR)	1034 (550–4395)
Median pleural fluid glucose, mmol/L (IQR)	4.9 (1.4–7.9)
Mean pleural fluid pH (SD)	8.0 ± 0.49
Intercostal catheter	
> 1 intercostal catheter, n (%)	11 (36.7)
Small bore intercostal catheter, ≤ 15 French, n (%)	26 (86.7)

IQR interquartile range, SD standard deviation, LDH lactate dehydrogenase, ULN upper limit of normal

## Discussion

Majority of patients (90%) were successfully treated and none required surgery for pleural infection. The clinical success was corroborated by significant improvements in radiographic clearance and pleural fluid drainage.

**Table 2** Microbiology in pleural fluid cultures

Microorganism cultured in pleural fluid	N (%)
<b>Negative cultures</b>	<b>22 (73.3)</b>
<b>Positive pleural fluid cultures</b>	<b>8 (26.7)</b>
<i>Gram positive organism</i>	1 (3.3)
Rhodococcus equi	1 (3.3)
<i>Gram negative organism</i>	6 (23.4)
Klebsiella pneumoniae sp.	4 (16.7)
Klebsiella ESBL	1 (3.3)
Enterobacter CRE	1 (3.3)

ESBL extended spectrum beta lactamase, CRE carbapenem resistance enterobacteriaceae

This study demonstrated a comparable success rate to previous studies [7, 8]. Comparison of clinical outcomes between studies should be made with caution due to the differences in patients' cohorts, clinical populations and study methodologies.

Majority (19.9%) had major life limiting diseases (carcinoma and end stage renal disease) who were unfit for surgery. Our baseline data showed our study cohort had significant pleural infection, as evidenced by high LDH, positive pleural fluid culture or septated effusion visualised by thoracic ultrasonography. Pleural fluid pH analysis may be inaccurate in this study due to our samples were not transported in heparinised blood gas syringe or measured in blood gas analyser. It was measured with litmus paper.

A longer hospital stay observed in our study as our cohort mainly those with poor drainage and failed medical therapy; in contrast with MIST-2 trial, intrapleural therapy were given immediately after randomisation. Concurrent bacteremia or other organ abscess that required longer parenteral antibiotics therapy also impact the length of stay. Furthermore, we do not have outpatient parenteral antimicrobial therapy service and these patients had to stay to complete the intended duration of parenteral antibiotics.

Dosing of t-PA used for intrapleural fibrinolysis varies from 4 to 100 mg per day [7, 14, 19–21], while the dose of intrapleural alteplase (t-PA) used in MIST-2 at 10 mg with supplemental pulmozyme (DNase) 5 mg twice daily for six doses is still empiric choice [7]. The rationale of this modified regimen of 16 mg t-PA with 5 mg DNase for total 3 doses that administered sequentially within 24 h reduced the frequency and time consuming for health care provider on administration of the drugs.


We propose that this modified regimen of t-PA and DNase offer an alternative therapeutic option for patients that are unfit or refuse surgical intervention but persistent pleural infection. We have demonstrated similar


**Table 3** Clinical outcomes

Clinical outcomes	Values
Treatment success, n, %	27 (90)
Surgical referral, n, %	0 (0)
Survival upon hospital discharge, n, %	30 (100)
Mortality at 30 days, n, %	3 (10)
Median length of hospital stay, days (IQR)	17 (11.7–24.2)
Median length of stay from first dose intrapleural therapy, days (IQR)	
Median duration of intercostal catheter in pleural cavity, days (IQR)	8 (4.8–12)
Median duration of intercostal catheter in pleural cavity post first dose intrapleural therapy, days (IQR)	
Patients who received $\leq 2$ doses intrapleural therapy, n (%)	10 (8–14.3)
	6 (4–7.3)
	8 (26.7)
<b>Adverse events<sup>a</sup>, n, %</b>	
Chest pain requiring escalation of analgesics	6 (20)
Gastrointestinal bleed	1 (3.3)
Clinical deterioration	1 (3.3)
Hemoptysis	1 (3.3)

IQR interquartile range, SD standard deviation, CRP C-reactive protein, WBC white cell count

<sup>a</sup> Same patient might experienced more than one adverse events





**Fig. 3** Cumulative volume of pleural fluid drained ( $n = 30$ ) in the 24 h before treatment (baseline), at 24 h and 72 h post first dose of intrapleural t-PA/DNase.  $P < 0.05$  by Friedman's ANOVA followed by post hoc test. IQR interquartile range

treatment success comparable to other studies [7, 8, 12]; as evidenced by improvement on pleural fluid drainage and reduction in pleural opacity on day 7 chest x-ray was approximately 50% from the baseline using intrapleural 16 mg t-PA with 5 mg DNase. The mechanism of action of t-PA and DNase in pleural cavity remain unclear. Studies suggested that IPFT may trigger the monocyte chemoattractant protein 1 (MCP-1) pathway which promote pleural fluid formation and subsequently causes a therapeutic lavage effect that increases pleural fluid drainage [22, 23].

Majority of our population (86.7%) was treated with small bore intercostal catheter ( $\leq 15$  French) as small bore chest drains have been shown experienced less pain than the larger one [24].

Bleeding risk has been a concern with intrapleural fibrinolysis although the mechanism of action t-PA and DNase in pleural space still unknown. Reported major adverse events (9.9%) in this study was slightly higher

than previous studies [7, 8]. Both patients had underlying comorbidities (advanced carcinoma and end stage renal disease) might contribute to the occurrence of bleeding event and clinical deterioration rather than purely due to the side effects of fibrinolytic agent. The contribution of t-PA or DNase to the bleeding event in our patient is uncertain as t-PA has short systemic half-life of 4–6 min and his GI bleed recurred 7 days after stopped intrapleural t-PA/DNase.

Chest pain was the main adverse effect, 20% patients requiring escalation of analgesia similar to previous studies that using conventional regimen [7, 8, 25].

There were some limitations to our study. It was a single centre, prospective one-arm study. Thus, there is some difficulty in interpreting the results due to absence of control group. A multicentre randomised, placebo-controlled study should be conducted to assess the efficacy and safety of the optimal dose of combined t-PA/DNase in treatment of pleural infection due to small number of

cases seen in a single institution. Furthermore, the criteria to perform surgery or insert an additional drain were not clearly protocolled; treatment decisions were made by the physicians which may have led to heterogeneity in management.

## Conclusion

This short duration modified regimen intrapleural 16 mg t-PA with 5 mg DNase is safe and effective in the management of poorly drained pleural infection. Administration of IPFT can be a rescue therapy for those who unfit for surgery with persistent pleural infection. In future, a large randomised placebo-controlled study could be conducted to evaluate the effectiveness and safety of different dosing regimen of intrapleural t-PA/DNase.

## Abbreviations

IPFT: Intrapleural fibrinolysis therapy; t-PA: Alteplase; DNase: Pulmozyme; IQR: Interquartile range; SD: Standard deviation; LDH: Lactate dehydrogenase; ULN: Upper limit of normal; ESBL: Extended Spectrum Beta Lactamase; CRE: Carbapenem resistance Enterobacteriaceae.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12890-022-01995-z>.

**Additional file 1:** Digital measurement on pleural opacity on chest X-ray.

## Acknowledgements

The authors would like to thank to the Dean of Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Professor Dr Abdul Halim Abdul Gafor for his support and encourage us to publish this research.

## Author contributions

Conceptualization: MFAH. Data curation: XKC, MFAH, AYB. Formal analysis: XKC, NANI, NFNF, SZSZ. Funding acquisition: MFAH. Methodology: XKC, MFAH. Project administration: XKC, MFAH, BHN, NNNA, GSL. Supervision: MFAH, AYB. Writing- original draft: XKC. Writing, review and editing manuscripts: XKC, MFAH, AYB. The author(s) read and approved the final manuscript.

## Funding

This study received fundamental grant from the Universiti Kebangsaan Malaysia. No funders had a role in the design of the study, data collection, analysis and data interpretation, or writing of the manuscript.

## Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

## Declarations

### Ethics approval and consent to participate

This study was approved by the Medical Ethics Committee of Universiti Kebangsaan Malaysia Medical Centre, and it is in accordance with the Helsinki Declaration (IV adaptation). Written informed consent was obtained from all participants. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

<sup>1</sup>Respiratory Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Kuala Lumpur, Malaysia. <sup>2</sup>Department of Radiology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia. <sup>3</sup>Department of Paediatrics, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia. <sup>4</sup>Department of Pharmacy, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.

Received: 19 February 2022 Accepted: 3 May 2022

Published online: 17 May 2022

## References

- Hassan M, Patel S, Sadaka AS, Bedawi EO, Corcoran JP, Porcel JM. Recent insights into the management of pleural infection. *Int J Gen Med*. 2021;14:3415–29.
- Davies HE, Davies RJO, Davies CWH. Management of pleural infection in adults: British Thoracic Society pleural disease guideline. *Thorax*. 2010;65(Suppl 2):ii41–53.
- Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. *Cochrane Database Syst Rev*. 2008;2:Cd002312.
- Maskell NA, Davies CWH, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. *New England J Med*. 2005;352(9):865–74.
- Bouros D, Schiza S, Patsourakis G, Chalkiadakis G, Panagou P, Sifakas N. Intrapleural Streptokinase versus Urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study. *Am J Respir Crit Care Med*. 1997;155:291–5.
- Hamblin SE, Furmanek DL. Intrapleural tissue plasminogen activator for the treatment of parapneumonic effusion. *Pharmacother J Hum Pharmacol Drug Ther*. 2010;30(8):855–62.
- Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. *N Engl J Med*. 2011;365(6):518–26.
- Piccolo F, Pitman N, Bhatnagar R, Popowicz N, Smith NA, Brockway B, et al. Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery. *Ann Am Thoracic Soc*. 2014;11(9):1419–25.
- Piccolo F, Popowicz N, Wong D, Lee YCG. Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection. *J Thorac Dis*. 2015;7(6):999–1008.
- Majid A, Kheir F, Folch A, Fernandez-Bussy S, Chatterji S, Maskey A, et al. Concurrent intrapleural instillation of tissue plasminogen activator and DNase for pleural infection. A single-center experience. *Ann Am Thoracic Soc*. 2016;13(9):1512–8.
- Altmann ES, Crossingham I, Wilson S, Davies HR. Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema. *Cochrane Database Syst Rev*. 2019;10:1158.
- Mehta HJ, Biswas A, Penley AM, Cope J, Barnes M, Jantz MA. Management of intrapleural sepsis with once daily use of tissue plasminogen activator and deoxyribonuclease. *Respir Int Rev Thoracic Dis*. 2016;91(2):101–6.
- Gilbert CR, Gorden JA. Use of intrapleural tissue plasminogen activator and deoxyribonuclease in pleural space infections: an update on alternative regimens. *Curr Opin Pulm Med*. 2017;23(4):371–5.
- Thommi G, Shehan CJ, McLeay MT. Fibrinolytics in parapneumonic effusions/empyemas. *Chest*. 2014;146(3):e103–4.
- Abu-Daff S, Maziak DE, Alshehab D, Threader J, Ivanovic J, Deslaurier V, et al. Intrapleural fibrinolytic therapy (IPFT) in loculated pleural effusions—analysis of predictors for failure of therapy and bleeding: a cohort study. *BMJ Open*. 2013;3(2):e001887.
- Semba CP, Weck S, Patapoff T. Alteplase: stability and bioactivity after dilution in normal saline solution. *J Vasc Interv Radiol JVIR*. 2003;14(1):99–102.



17. Popowicz N, Bintcliffe O, De Fonseca D, Blyth KG, Smith NA, Piccolo F, et al. Dose De-escalation of intrapleural tissue plasminogen activator therapy for pleural infection. The alteplase dose assessment for pleural infection therapy project. *Ann Am Thoracic Soc*. 2017;14(6):929–36.
18. Abdul HMF, Rahaman KM. Retrospective review in a single tertiary centre of patients receiving intrapleural recombinant tissue plasminogen activator (rTPA) with alteplase monotherapy in infective and non infective complex effusion. *CHEST*. 2019;155(4):83.
19. Faisal M, Fazlin M, Ng BH, Nuratiqah N, Andrea YLB. Low dose intrapleural alteplase and pulmozyme (DNase) in two post-surgical patients with pleural sepsis. *Respir Med Case Rep*. 2020;30:101111.
20. Faisal M, Farhan R, Cheong XK, Ng BH, Nuratiqah N, Andrea YB. Short-course modified regimen intrapleural alteplase and pulmozyme (DNase) in pleural infection. *Respir Med Case Rep*. 2020;31:101168.
21. Cheong XK, Yu-Lin Ban A, Abdul Hamid MF. Short-course intrapleural alteplase and DNase in complex effusion with bleeding risk. *Respir Med Case Rep*. 2020;8(7):e00648.
22. Lansley SM, Cheah HM, Vergiliana JFV, Chakera A, Lee YCG. Tissue plasminogen activator potently stimulates pleural effusion via a monocyte chemotactic protein-1–dependent mechanism. *Am J Respir Cell Mol Biol*. 2015;53(1):105–12.
23. Kanellakis NI, Wrightson JM, Halifax R, Bedawi EO, Mercer R, Hassan M, et al. Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients. *BMJ Open Respir Res*. 2019;6(1):e000440.
24. Rahman NM, Maskell NA, Davies CW, Hedley EL, Nunn AJ, Gleeson FV, et al. The relationship between chest tube size and clinical outcome in pleural infection. *Chest*. 2010;137(3):536–43.
25. Robitaille C, Dupont C, Valenti D, Spicer J, Sirois C, Gonzalez AV, et al. Retrospective review of intrapleural therapy for pleural infections: “Real life” outcomes and challenges. *Can J Respir Crit Care Sleep Med*. 2018;2(4):218–23.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

